Northwest Notes: Jazz, Blazers, Nurkic, Wolves - hoopsrumors.com

The Jazz still have an open spot on their 15-man roster and they’re likely to fill it sooner or later, writes Tony Jones of The Athletic. That could happen by Thursday’s deadline, but if Utah doesn’t add a player in a deadline deal, the team figures to scour the buyout market after March 25.

As for what type of player the Jazz may be targeting, league sources tell Jones that the club is in the market for a perimeter defender who could perhaps play 10-15 minutes against top perimeter scorers. Ideally, that player would also be able to knock down three-pointers, but there won’t be many solid three-and-D wings available for cheap on the trade market or in free agency.

The Jazz won’t be upset if they don’t find that player by Thursday, according to Jones, who says the club is happy with its current rotation and team chemistry.

Here’s more from around the Northwest:

The Trail Blazers became the latest team to have many of their players receive the coronavirus vaccine. The team announced today in a press release that 12 players received their first dose of the Moderna COVID-19 vaccine, having received access to an excess supply from the Confederated Tribes of Grand Ronde.
Although Jusuf Nurkic remains sidelined for the Trail Blazers, the wrist he underwent surgery on in January has been cleared, according to Jason Quick of The Athletic, who notes (via Twitter) that Nurkic’s return is now being delayed by a right calf strain.
The Timberwolves will welcome fans back to the Target Center beginning on April 5 vs. Sacramento, the team announced in a press release. The club didn’t clarify exactly what the limited capacity will be in its arena for the rest of the season.

Let's block ads! (Why?)